Sex differences in the expression of haemorheological determinants in individuals with atherothrombotic risk factors and in apparently healthy people

D Zeltser, O Rogowski, S Berliner, T Mardi, D Justo, J Serov, M Rozenblat, D Avitzour, I Shapira

Background: Increased red cell aggregation can be detrimental, leading to slow capillary blood flow and tissue hypoxaemia. Sex differences in the degree of erythrocyte adhesiveness/aggregation in the peripheral blood have not been clearly shown.

Objectives: To determine whether there are sex differences in the expression of erythrocyte adhesiveness/aggregation in the peripheral blood in individuals with atherothrombotic risk factors and in apparently healthy people.

Methods: From a cohort of 965 participants in the Tel Aviv Medical Centre inflammation survey, 192 pairs of different sex were matched for age, body mass index, hip and waist circumferences, cardiovascular risk factors, and the intake of active cardiovascular drugs.

Results: Women had an enhanced degree of red cell aggregation (p < 0.0005) as well as increased concentrations of inflammation sensitive proteins including fibrinogen and C reactive protein. Women had a lower haemoglobin concentration than men, but this did not affect the degree of erythrocyte adhesiveness/aggregation.

Conclusions: The significant increase in red blood cell adhesiveness/aggregation in the peripheral blood of women with atherothrombosis could be relevant to the more eventful course that some women experience during and following acute ischaemic disease.

It has been shown repeatedly that enhanced red blood cell aggregation is associated with slow capillary blood flow, disturbed microcirculatory blood flow, and tissue hypoxaemia. Therapeutic interventions directed at reducing this deleterious haemorheological effect might attenuate the tendency for cells to adhere to each other and aggregate, thus improving a patient’s clinical condition.

Studies in the past did not take into account the potential differences between women and men regarding red blood cell adhesiveness/aggregation. Such differences could have an effect on the different prognosis of acute vascular events between women and men. In this study we show that there are significant differences in the degree of erythrocyte adhesiveness/aggregation in the peripheral venous blood between women and men. We discuss the relevance of this for potential microcirculatory obstruction under conditions of vascular occlusion and for the phenomenon of non-reperfusion.

METHODS

Study population

This cross sectional study involved participants from the following sources:

- apparently healthy employees of the Tel Aviv Medical Centre and Tel Aviv Municipality (Israel), including members of the medical staff and retired employees
- individuals with atherothrombotic risk factors who were being followed up in various outpatient clinics of the medical centre, including clinics for diabetes, hypertension, and metabolic disorders
- people with a history of a clinically overt vascular disease, including a history of coronary artery bypass grafting, myocardial infarction, cerebrovascular accident, or peripheral artery occlusive disease
- individuals who had been evaluated in our outpatient health screening programme.

All the subjects included in the survey gave their written informed consent according to the instructions of the local ethics committee. Recruitment was based on local announcements and advertisements in the monthly payroll bill of the medical personnel, as well as an appeal to the patients in the various outpatient clinics to participate in the inflammation survey.

We excluded any individuals with an underlying inflammatory disease (arthritis, inflammatory bowel disease, and so on) as well as those with any infection or other inflammatory condition, including infarction, surgery, or angiography, during the six months preceding the recruitment into the present study. We also excluded any individual treated with steroids or non-steroidal anti-inflammatory drugs, except for aspirin at doses less than 325 mg/day. This dose was chosen because we have found that the intake of up to 325 mg of aspirin a day does not have a significant effect on the degree of erythrocyte adhesiveness/aggregation (unpublished data).

Population study design

From the whole cohort of subjects, we tried as far as possible to match pairs of different sex with regard to age, body mass index (BMI), hip and waist circumferences, and cardiovascular risk factors, in decreasing order of importance. In order to do this, we first excluded any individual with a history of clinically overt vascular disease, as mentioned above, or any woman treated with hormonal replacement therapy, owing to its proven effect on C reactive protein concentrations and possibly on inflammation. We then excluded any individual with missing values of any of the anthropometric variables or inflammatory indices (high sensitivity C reactive protein (hs-CRP) and fibrinogen).
**Definition of risk factors score**

Diabetes mellitus was defined as a blood glucose concentration of ≥7 mmol/l fasting or >11 mmol/l random on two separate occasions, or being treated with insulin or oral antidiabetic agents. Arterial hypertension was defined as a blood pressure of ≥140/90 mm Hg or being on anti-hypertensive drugs. Hyperlipidaemia was defined as having a low density lipoprotein (LDL) cholesterol concentration of ≥3.4 mmol/l or a triglyceride concentration of >1.8 mmol/l, or being on HMG-CoA reductase inhibitors or fibrates.

**Laboratory variables**

The white blood cell count and differential count were done using a Coulter STKS automatic cell analyser (Beckman Coulter, Nyon, Switzerland); the erythrocyte sedimentation rate (ESR) by Westergren’s method, fibrinogen concentration by the method of Clauss using a Sysmex 600 autoanalysers (Sysmex Corporation, Hyaga, Japan); and hs-CRP by Rifai’s method, using a Behring BN II nephelometer (DADA Boehringer, Marburg, Germany).

**The Erythrosense biomarker**

This involved a simple slide test. Venous blood from the antecubital vein was obtained between 08.00 and 11.00 hours following an overnight fasting. Blood was drawn into a syringe containing sodium citrate (one volume of 3.8% sodium citrate to three volumes of whole blood). One drop of the citrated whole blood was trickled (from a height of 3 cm) onto a slide inclined at an angle of 30° and allowed to run down by gravity, leaving a fine film. The slides were left to dry in that position, at room temperature. A technician who was blinded to the clinical and laboratory results of the patients scanned the slides using an image analysis system (Inflamet, Inflamet Co, Tel Aviv, Israel).

**The inflammation meter (Inflamet)**

This system consists of a personal computer equipped with a Matrox Meteor colour frame grabber (Matrox Co, Montreal, Canada), a colour charge couple device (CCD) camera, and a microscope which was operated at 200× magnification, resulting in an image resolution of 0.4 micron per pixel. Nine images were taken from each slide. The fields of view were chosen systematically to sample different regions on the slide. Each image is processed separately and the outputs are then averaged to form the final slide outputs. The nine fields of view cover a total area of 0.6 mm². A variable called the erythrocyte percentage (EP) was chosen to represent the degree of red blood cell adhesiveness/aggregation. This is essentially a measurement of the area that is covered by the red blood cells. In the absence of aggregation the covered area is 100%, whereas with the appearance of enhanced erythrocyte adhesiveness/aggregation this percentage is lower. Thus the higher the degree of aggregation, the lower is the area covered by the cells, and vice versa. This is because during cell aggregation, free spaces are formed between the aggregated cells. These free spaces are subtracted from total slide area covered by red blood cells. A typical example is represented in fig 1.

**Inflamet variabilities**

The coefficient of variation for the erythrocyte aggregation/adhesiveness test (EAAT)—when one person prepared and read the different slides of a patient with inflammation—was 0.14. We repeated this evaluation in five different patients with the same results. When nine different people prepared slides from the same patient the coefficient was 0.07. It was 0.1 when the same person read the same slide 10 times. The interobserver variability of this test was discussed by us in a study done on 273 individuals with various degrees of infection/inflammation. We found a substantial interobserver concordance which was at least as good as that obtained when a chest x-ray is shown to different specialists in radiology. In addition, we have recently reported the day to day variation in EAAT in a group of 30 individuals who had repeated EAAT determinations (between seven and 13 examinations per patient). In that study, we were able to show that the daily fluctuations in the test are comparable to other commonly used variables of the acute phase response, including C reactive protein, white blood cell count, ESR, and fibrinogen concentrations.

**Statistical analysis**

All continuous variables are summarised and displayed as mean (SD) for each sex separately, and the categorical data are summarised and displayed as the number of persons in each group plus the percentage in the group. For continuous variables, a comparison between the sexes was made using Student’s t test for paired samples. For all the categorical variables the paired sign test was used to test the possible difference between the groups. In order to reject the hypothesis that the lower haemoglobin concentration in women contributes to their enhanced erythrocyte adhesiveness/aggregation, we calculated haemoglobin adjusted Pearson’s correlation coefficients between the results of the Erythrosense biomarker and the inflammatory variables hs-CRP and fibrinogen, and compared them with the non-haemoglobin adjusted correlation. In addition we calculated different linear regression models to assess the contribution of haemoglobin, hs-CRP, and fibrinogen to the prediction of the degree of the erythrocyte adhesiveness/aggregation. In both the correlations and the linear regression, a logarithmic
Sex differences in erythrocyte aggregation also higher in men (table 1). Greater among the men; as a result the waist/hip ratio was seen that although full match was achieved for age, BMI, and anthropometric variables, it can be met all the inclusion criteria. We were able to match 192 pairs on the basis of age and anthropometric variables. It can be

**RESULTS**

There were 852 individuals (420 men and 432 women) who were excluded from effects on erythrocyte adhesiveness/aggregation. We found that in all possible models in both sexes, haemoglobin concentration showed no significant difference between the sexes. Thus haemoglobin concentration did not contribute to the enhanced degree of erythrocyte adhesiveness/aggregation in women (table 5).

Finally we report the results of the degree of erythrocyte adhesiveness/aggregation (expressed as the erythrocyte percentage, EP) as well as those relating to lipid and inflammatory variables (table 4). An enhanced degree of erythrocyte adhesiveness/aggregation was found in the women compared with the men, along with increased concentrations of the inflammation sensitive proteins hs-CRP and fibrinogen. In addition, the women had a lower mean number of risk factors per individual and found a percentage, EP, as well as those relating to lipid and inflammatory variables (table 4). An enhanced degree of erythrocyte adhesiveness/aggregation was found in the women compared with the men, along with increased concentrations of the inflammation sensitive proteins hs-CRP and fibrinogen. In addition, the women had a lower mean number of risk factors per individual and found a

**DISCUSSION**

It has been shown in the past that there are sex specific differences in cardiovascular mortality, to the detriment of women. The possibility that enhanced inflammation and red blood cell adhesiveness/aggregation in women might contribute to a worse haemorheological profile has not been considered in the past. This could be relevant to the pathophysiology of microcirculatory flow in conditions of vascular obstruction, occlusion of small vessels, slow flow, and cell stagnation within the capillary network. Indeed it has been shown that enhanced red cell aggregation can contribute to tissue hypoxaemia.

We have recently adopted a whole blood slide test and image analysis to quantify the tendency of red blood cells to adhere to each other and aggregate in the peripheral venous blood. This Erythrose biomarker is based on the known

### Table 1 Basic characteristic including the anthropometric variables

<table>
<thead>
<tr>
<th></th>
<th>Women (n = 192)</th>
<th>Men (n = 192)</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>48.8 (11.7)</td>
<td>48.7 (11.9)</td>
<td>NS</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>30.1 (5.7)</td>
<td>30.5 (5.6)</td>
<td>NS</td>
</tr>
<tr>
<td>Waist (cm)</td>
<td>99.6 (13.5)</td>
<td>105.4 (13.0)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>Hip (cm)</td>
<td>105.9 (10.7)</td>
<td>105.0 (10.5)</td>
<td>NS</td>
</tr>
<tr>
<td>Waist/hip ratio</td>
<td>0.94 (0.11)</td>
<td>1.00 (0.8)</td>
<td>&lt;0.0005</td>
</tr>
</tbody>
</table>

Values are mean (SD); *Significance was determined by paired t test between the sexes.

BMI, body mass index.

### Table 2 Number and percentage of atherothrombotic risk factors in women and men matched for age and anthropometric variables

<table>
<thead>
<tr>
<th>Atherothrombotic risk factor</th>
<th>Women</th>
<th>Men</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoker</td>
<td>66 (34.4%)</td>
<td>78 (40.6%)</td>
<td>NS</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>11 (5.7%)</td>
<td>7 (3.6%)</td>
<td>NS</td>
</tr>
<tr>
<td>Hyperlipidaemia</td>
<td>59 (30.7%)</td>
<td>47 (24.3%)</td>
<td>NS</td>
</tr>
<tr>
<td>Hypertension</td>
<td>28 (14.6%)</td>
<td>39 (20.5%)</td>
<td>NS</td>
</tr>
<tr>
<td>Mean (SD) number of risk factors per individual</td>
<td>0.85 (0.84)</td>
<td>0.89 (0.83)</td>
<td>NS</td>
</tr>
</tbody>
</table>

*Paired t test.

### Table 3 Number and percentage of individuals taking cardiovascular drugs that might have an effect on the inflammatory response or have haemorheological relevance

<table>
<thead>
<tr>
<th>Drug</th>
<th>Women</th>
<th>Men</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>7 (3.6%)</td>
<td>19 (9.9%)</td>
<td>0.023</td>
</tr>
<tr>
<td>Nitrites</td>
<td>0 (0%)</td>
<td>1 (0.5%)</td>
<td>NS</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>0 (0%)</td>
<td>1 (0.5%)</td>
<td>NS</td>
</tr>
<tr>
<td>β Blockers</td>
<td>0 (0%)</td>
<td>3 (1.6%)</td>
<td>0.016</td>
</tr>
<tr>
<td>β Blockers</td>
<td>13 (6.8%)</td>
<td>12 (6.3%)</td>
<td>NS</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>7 (3.6%)</td>
<td>15 (7.8%)</td>
<td>NS</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>8 (4.2%)</td>
<td>13 (6.8%)</td>
<td>NS</td>
</tr>
<tr>
<td>Angiotensin II receptor blocker</td>
<td>4 (2.1%)</td>
<td>2 (1.0%)</td>
<td>NS</td>
</tr>
<tr>
<td>HMG-CoA reductase blockers</td>
<td>9 (4.7%)</td>
<td>5 (2.6%)</td>
<td>NS</td>
</tr>
<tr>
<td>Fibrates</td>
<td>3 (1.6%)</td>
<td>2 (1.0%)</td>
<td>NS</td>
</tr>
</tbody>
</table>

*Paired t test. ACE, angiotensin converting enzyme; HMG-CoA, hydroxymethylglutaryl coenzyme A.

### Table 4 Comparison between women and men of erythrocyte adhesiveness/aggregation (expressed as erythrocyte percentage) together with lipid and inflammatory variables

<table>
<thead>
<tr>
<th>Variable</th>
<th>Women</th>
<th>Men</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP (%)</td>
<td>79.1 (15.0)</td>
<td>91.4 (10.3)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>ESR (mm/h)</td>
<td>26.3 (15.5)</td>
<td>13.3 (10.8)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>hs-CRP (mg/l)</td>
<td>5.8 (7.4)</td>
<td>3.8 (6.3)</td>
<td>0.004</td>
</tr>
<tr>
<td>Fibrinogen (mg/dl)</td>
<td>323 (60)</td>
<td>288 (60)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>WBCC (10³ cells/µl)</td>
<td>7.36 (2.00)</td>
<td>7.06 (1.89)</td>
<td>NS</td>
</tr>
<tr>
<td>PMNMC (10³ cells/µl)</td>
<td>4.39 (1.58)</td>
<td>4.25 (1.51)</td>
<td>NS</td>
</tr>
<tr>
<td>Monocytes (10³ cells/µl)</td>
<td>0.54 (0.38)</td>
<td>0.56 (0.16)</td>
<td>NS</td>
</tr>
<tr>
<td>Haemoglobin (g/dl)</td>
<td>13.0 (0.99)</td>
<td>14.9 (0.9)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>MCV (fl)</td>
<td>86.0 (5.2)</td>
<td>86.9 (4.1)</td>
<td>NS</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>5.74 (1.06)</td>
<td>5.69 (1.11)</td>
<td>NS</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/l)</td>
<td>3.54 (0.9)</td>
<td>3.62 (0.96)</td>
<td>NS</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/l)</td>
<td>1.45 (0.39)</td>
<td>1.34 (0.31)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.64 (0.97)</td>
<td>1.87 (1.81)</td>
<td>0.033</td>
</tr>
</tbody>
</table>

Values are mean (SD).

*Paired t test. EP, erythrocyte percentage; ESR, erythrocyte sedimentation rate; HDL, high density lipoprotein; hs-CRP, high sensitivity C reactive protein; LDL, low density lipoprotein; MCV, mean corpuscular volume; PMN, polymorphonuclear leucocyte count; WBCC, white blood cell count.
observations that multiple inflammation sensitive proteins—including fibrinogen, immunoglobulins, haptoglobin, caerulo-plasmin, α-1 acidic protein, and hs-CRP—are associated with the induction or maintenance of enhanced red blood cell aggregation.21–24 Thus our biomarker uses the erythrocyte as a sensor for the presence of these adhesion macromolecules in the plasma milieu around and between the cells. The resulting degree of cell adhesiveness/aggregation is probably a summarised effect of these proteins on the tendency of the cells to adhere to each other and aggregate. We have already shown that enhanced red blood cell adhesiveness/aggregation correlates significantly with the presence of enhanced fibrinogen concentrations25 and with the degree of the patient’s inflammatory response;26 that it can be induced by the intravenous infusion of immunoglobulins,7 and that it is abolished by plasmapheresis.24

The possibility that there might be sex differences in the tendency of red blood cells to adhere to each other and aggregate has not been evaluated in a systematic way in the past. Our study is the first to match women and men for multiple factors that might affect the inflammatory response, the concentrations of inflammation sensitive proteins, and the degree of red cell adhesiveness/aggregation. These include age, obesity, atherothrombotic risk factors, and vascular events, as well as the intake of therapeutic drugs. The results are significant in that they show a clear sex difference in the degree of red cell adhesiveness/aggregation. The difference is probably related to the enhanced inflammatory response and the presence of increased fibrinogen concentrations, and not to a lower haemoglobin concentration in women.

An adverse outcome in individuals with enhanced inflammation and erythrocyte adhesiveness/aggregation has been shown by us in several small cohorts in the past.21–24 It is known that increased concentrations of fibrinogen may have harmful rheological implications.27–29 In addition, a heightened baseline inflammatory profile, including increased C reactive protein, could contribute to an adverse vascular course in individuals with acute ischaemic diseases.30 Thus the enhanced erythrocyte adhesiveness/aggregation that is found in women with inflammation and increased concentrations of inflammation sensitive proteins could be a factor in the pathophysiology of cell stagnation in occluded microvessels. A better understanding of these pathophysiological events should lead to therapeutic interventions to reduce inflammation and improve the rheological profile.

A potential effect of hormonal therapy has been noted by other investigators in the past.31–33 None of the 81 postmenopausal women in this study was on hormonal replacement therapy, and only 10 of the 111 premenopausal women were on oral contraceptives. Analysis of the premenopausal women who were not on contraceptives did not alter the results reported here. However, our study was not designed to address the issue of the potential effect of hormonal replacement therapy or oral contraceptives on the haemorheological variables.

### Conclusions

There are sex differences with respect to the degree of inflammation, the concentrations of inflammation sensitive protein, and red blood cell adhesiveness/aggregation in the peripheral blood. A better understanding of these sex differences could pave the way for a more potent anti-inflammatory approach to treating women at risk of future vascular events.

### Authors’ affiliations

D Zeltser, O Rogowski, S Berliner*, T Mardi, D Justo, J Serov, M Rozenblat, I Shapiro, Department of Internal Medicine “D”, Tel Aviv Sourasky Medical Centre, Tel Aviv University, Tel Aviv, Israel

D Avitzour, Timorim Technologies, Jerusalem, Israel

*Professor Berliner is a shareholder of Inflamet Ltd, Tel Aviv, Israel

### REFERENCES

Non-compaction of the left ventricle

Non-compaction of the left ventricle is a rare congenital cardiomyopathy characterised by a loosened spongy myocardium. The disorder may be associated with facial dysmorphism and familial recurrence and is caused by intrauterine arrest of compaction of the loose interwoven meshwork.

Left ventricular angiography (below left), cardiac magnetic resonance imaging (MRI) (below centre), and echocardiography (below right) typically reveal a dilated hypocontractile left ventricle with a two-tailed wall; the inner zones of heavily spongious, trabecularised endocardial layers with deep intertrabecular recesses can be distinguished from thin outer zones of compacted myocardium. Histological examination confirms the spongy appearance with deep intertrabecular recesses, lined by endothelium, which spread close to the epicardial surface.

Prompt recognition of the disease is mandatory because of its high mortality and morbidity. Heart failure, thromboembolic events, and ventricular arrhythmias all have been reported. Besides familial screening and risk stratification, treatment is directed to prevent and manage heart failure, ventricular arrhythmias, and cardiac thromboembolism.

M Vanderheyden
J Bartunek
M Goethals
Marc.Vanderheyden@olvz-aalst.be

Images in Cardiology

Non-compaction of the left ventricle

On-compaction of the left ventricle is a rare congenital cardiomyopathy characterised by a loosened spongy myocardium. The disorder may be associated with facial dysmorphism and familial recurrence and is caused by intrauterine arrest of compaction of the loose interwoven meshwork.

Left ventricular angiography (below left), cardiac magnetic resonance imaging (MRI) (below centre), and echocardiography (below right) typically reveal a dilated hypocontractile left ventricle with a two-tailed wall; the inner zones of heavily spongious, trabecularised endocardial layers with deep intertrabecular recesses can be distinguished from thin outer zones of compacted myocardium. Histological examination confirms the spongy appearance with deep intertrabecular recesses, lined by endothelium, which spread close to the epicardial surface.

Prompt recognition of the disease is mandatory because of its high mortality and morbidity. Heart failure, thromboembolic events, and ventricular arrhythmias all have been reported. Besides familial screening and risk stratification, treatment is directed to prevent and manage heart failure, ventricular arrhythmias, and cardiac thromboembolism.

M Vanderheyden
J Bartunek
M Goethals
Marc.Vanderheyden@olvz-aalst.be
Non-compaction of the left ventricle

M Vanderheyden, J Bartunek and M Goethals

*Heart* 2004 90: 281
doi: 10.1136/hrt.2003.019992

Updated information and services can be found at:
[http://heart.bmj.com/content/90/3/281](http://heart.bmj.com/content/90/3/281)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)